Fresh analysis indicates that individuals who stop using new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who halt traditional lifestyle programs.
Published data in a prominent health publication demonstrates that while obese individuals can lose about a fifth of their body weight while using the jabs, the mass returns at an average rate of 0.8 kg per month once they quit.
"People purchasing such drugs must be cognizant of the danger of quick rebound weight gain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of regain means a return to pre-treatment weight in about a year and a half.
Weighing Therapies
The research, which reviewed dozens of trials involving thousands of patients, compared the effects of the injectable medications with other pills.
The team emphasize that individuals who lose weight through diet and exercise typically have a more gradual weight regain—around 0.1 kg a month—after stopping.
The Reason for the Fast Regain
Doctors believe the mechanism of the drugs is key to understanding the accelerated weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone levels several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in appetite is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
The NHS suggest the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, considering the high risk of weight regain, the therapy should be considered life-long.
This view is echoed by drug manufacturers, who state that the results "underscore the long-term character of excess weight," similar to managing conditions like high blood pressure.
User Experiences
Users who have discontinued the medication describe a intense return of hunger.
"It felt as if a trigger flipping and you're instantly starving," described a patient.
This challenge is compounded if patients have not developed lasting lifestyle or habit changes during therapy.
Widespread Use
Survey data show that a significant number of adults in the UK have used these injections in the last 12 months, with demand being substantial.
- Use is greater among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent solution and lasting health benefits likely depends on integrated behavioural changes.
